Suppr超能文献

[慢性心房颤动的栓塞并发症]

[Embolic complications of chronic atrial fibrillation].

作者信息

Koenig A, Théolade R, Chauvin M, Brechenmacher C

机构信息

Service de cardiologie, CMCO, Strasbourg-Schiltigheim.

出版信息

Arch Mal Coeur Vaiss. 1992 Mar;85(3):315-23.

PMID:1575609
Abstract

Systemic embolism secondary to chronic atrial fibrillation usually affect the cerebral circulation. The risk of a cerebrovascular accident in patients with chronic atrial fibrillation, irrespective of the aetiology, is 1.8 to 7.5 times that of the general population. The embolic risk is 18 times greater in patients with atrial fibrillation related to the rheumatic heart disease. The risk of patients under 60 years of age with idiopathic atrial fibrillation does not seem to be different to that of the general population. The risk of early recurrence of embolism in the first 30 days ranges from 8 to 15%. The risk of late recurrence varies but seems to be higher than that of the general population. The prognosis of embolic cerebrovascular accidents is poor with a 20% mortality rate. The benefits of preventive therapy of embolism with oral anticoagulants have been clearly established in rheumatic atrial fibrillation and in other indications. In non-valvular atrial fibrillation the benefits have to be compared with the risks of treatment. The incidence of hemorrhage due to anticoagulant therapy is between 3 and 5% per year per patient (about 1% of severe haemorrhage). Three randomised studies of primary prevention have shown a significant reduction of the embolic risk in non-valvular atrial fibrillation treated by warfarin compared to patients on placebo. Only one study has shown a significant reduction of the embolic risk in patients under 75 years of age with non-valvular atrial fibrillation treated with 325 mg/day of aspirin. However, anticoagulant therapy does not seem necessary in carefully selected patients under 60 years of age with idiopathic atrial fibrillation (less than 5% of all patients).

摘要

慢性心房颤动继发的系统性栓塞通常影响脑循环。慢性心房颤动患者发生脑血管意外的风险,无论病因如何,是普通人群的1.8至7.5倍。与风湿性心脏病相关的心房颤动患者的栓塞风险高18倍。60岁以下特发性心房颤动患者的风险似乎与普通人群无异。栓塞在最初30天内早期复发的风险为8%至15%。晚期复发风险各不相同,但似乎高于普通人群。栓塞性脑血管意外的预后很差,死亡率为20%。口服抗凝剂预防栓塞治疗在风湿性心房颤动及其他适应证中的益处已得到明确证实。在非瓣膜性心房颤动中,必须将益处与治疗风险进行比较。抗凝治疗导致出血的发生率为每年每位患者3%至5%(严重出血约为1%)。三项一级预防随机研究表明,与服用安慰剂的患者相比,华法林治疗的非瓣膜性心房颤动患者的栓塞风险显著降低。只有一项研究表明,每天服用325毫克阿司匹林治疗的75岁以下非瓣膜性心房颤动患者的栓塞风险显著降低。然而,对于精心挑选的60岁以下特发性心房颤动患者(占所有患者的不到5%),抗凝治疗似乎没有必要。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验